Fig. 5.
Fig. 5. CD8αβ expression on PBL from HIV-1 seropositive individuals at baseline and after initiation of highly active antiretroviral therapy (HAART). (A) The expression of the CD8αβ-heterodimer over a 16-week treatment period showed a significant increase (P < .008). (▴) Subject with the largest increase in CD8αβ expression; (▪) subject with the smallest change in CD8αβ expression. (B) Change of CD8αβ expression on PBL from the HIV-1 seropositive individual in the cohort of treated patients with the largest increase in CD4+ T lymphocytes/μL blood and CD8αβ MF. The CD8αβ MF showed an increase of 32 channels (baseline, 27; 16 weeks post-HAART, 59).

CD8αβ expression on PBL from HIV-1 seropositive individuals at baseline and after initiation of highly active antiretroviral therapy (HAART). (A) The expression of the CD8αβ-heterodimer over a 16-week treatment period showed a significant increase (P < .008). (▴) Subject with the largest increase in CD8αβ expression; (▪) subject with the smallest change in CD8αβ expression. (B) Change of CD8αβ expression on PBL from the HIV-1 seropositive individual in the cohort of treated patients with the largest increase in CD4+ T lymphocytes/μL blood and CD8αβ MF. The CD8αβ MF showed an increase of 32 channels (baseline, 27; 16 weeks post-HAART, 59).

Close Modal

or Create an Account

Close Modal
Close Modal